جستجوی مقالات مرتبط با کلیدواژه « استازولامید » در نشریات گروه « پزشکی »

Referral pain is one of the most common complications after laparoscopic cholecystectomy. The aim of this study was to evaluate and compare the effect of different doses of acetazolamide on postoperative pain in patients undergoing laparoscopic cholecystectomy with carbon dioxide gas.
In this double-blind clinical trial study, 90 patients who were candidates for laparoscopic cholecystectomy were enrolled and randomly divided into three groups. The first group was treated with acetazolamide (10 mg/kg up to 750 mg), the second group was treated with acetazolamide (5 mg/kg up to 375 mg), and the third group was treated with placebo (empty capsule) one hour before the operation. Then, the study variables were compared between three groups.
Findings: At the baseline, and 6, 12, and 18 hours after the operation, referral pain was significantly less to more in first, second, and third groups, respectively (P The usage of 10 mg/kg up to 750 mg of acetazolamide significantly reduced postoperative referral pain, and need to analgesia in patients undergoing laparoscopic cholecystectomy with carbon dioxide gas; but the complications of this dose were relatively higher, although were not severe.

Intraocular pressure (IOP) rise is the most common complication of Nd YAG laser posterior capsulotomy، and the aim of this study was to compare the effect of oral acetazolamide versus topical Co-biosopt in preventing IOP rise following Nd YAG laser posterior capsulotomy. This clinical trial was done on 200 patients who underwent laser Nd: YAG capsulotomy. First group received oral acetazolamide 250 mg q 6h and placebo drops q 8h and second group received Co-biosopt) timolol 0/5% and dorzolamide 2%) drops q 8h and oral placebo capsule q 6h. IOP was measured before and 24 hours after laser capsulotomy. Mean IOP of right and left eye 24 hours after capsulotomy in the acetazolamide group was significantly decreased as compared to the previous (P=0/001) and in Co-Biosopt group the values 24 hours after capsulotomy was significantly decreased as compared with the previous in right and left eye (P=0/001). According to oral acetazolamide side effects and desirable IOP reduction with Co-Biosopt that recently entered to Iran’s market and have typical domestic، this medication can be an option for preventing IOP rise after laser capsulotomy in a patient with posterior capsular opacification.

This study aimed at investigating the inhibitory effect of acetazolamide on the growth and proliferation of breast cancer cells (T47-D). The appearance of morphological symptoms of apoptosis was checked after staining with Annexin-PI using fluorescent microscope. Flow cytometric studies were used for determination of the amount and type of cellular death and also for analyzing the cell division cycle. The amounts of caspase-3 activity and DNA laddering were determined in the treated cells and compared with samples of the control group. Unilateral variance test was used to analyze data.

Carbon dioxide (Co2) is used during laparoscopy for producing pneumoperttoneum. Combination of this gas with irrigation fluid in the abdomen produces carbonic acid which creates two kinds of abdominal and referred pain to right shoulder. In the present research we have studied the effect of oral acetazolamide in reducing postoperative pain after laparoscopic cholecystectomy. This clinical trial was performed in 88 patients with cholelithiasis without any complication that were candidate for laparoscopic cholecystectomy. The patients devided randomly and equally in two groups. The experimental group received Acetazolamide (250mg orally 24 hours before surgery every 8 hours) and control group received placebo. Abdominal and shoulder pain measured using Mc Gill pain score by a person who was blind for both groups. Pain measurement was performed in four different times before and after the surgery discharge from recovery and 24 hours after surgery. Data were analyzed by using SPSS software. We observed that mean pain scores was significantly higher in acetazolamide group compared to the placebo group 24 hours after the operation (P0.05). Although acetazolamide can reduce abdominal pain referred to right shoulder by reducing acidity in peritoneal irrigation fluid but this drug can increase abdominal pain in the site of surgery with damaged tissues by producing tissue acidosis (as a side effect of drug).

In laparoscopic surgery CO2 is insufflated into the abdomen and may cause referred pain. So the aim of this study is to determine acetazolamide effect on postoperative pain after laparoscopic surgery. in a double blinded clinical trial, 60 patients who were going under laparoscopic surgery were divided into two groups. Before surgery 250 mg acetazolamide was administered to group A and placebo was administered to group B. Incisional pain and referred pain was measured using Visual Analog Scale (0-10) just after consciousness, 30 min after entering the recovery room, after entering the surgery ward and the day after surgery. Data was analyzed using SPSS. In both groups, 7 nephrectomy, 10 varicosel, 6 orchiopexy and 7 pieloplasty had been done. Incisional pain scores was not statistically different between two groups (P>0.05). But the referred pain was lower after acetazolamide administration than after placebo. (P<0.05) According to the results of this study, acetazolamide reduces referred pain after laparoscopic surgical procedures that are performed with abdominal insufflations of CO2.

Acetazolamide, a carbonic anhydrase inhibitor, is most efficient and beneficial in the treatment of glaucoma when used as a sustained release form. In the present work some sustained release matrices of the drug were formulated. Tragacanth and acacia gums matrices containing 500 mg of acetazolamide with ratios of gum to drug (RG/D) between 0.1-1 were formulated and the release study was conducted in buffer solution (pH=7.4) using USP dissolution apparatus I for 480 min. The drug release was affected by the kind of the gum as well as the RG/D values. In order to assess the efficiency of the gums, percent of drug dissolved up to any time was plotted against RG/D. The plot was named as gum efficiency curve which contained ascending and descending parts indicating two opposite effects of the gums on drug release i.e release increasing effect up to a certain RG/D and then at higher RG/Ds release decreasing effect. The corresponding turning points from ascending to descending part were 0.45 for tragacanth and 0.55 for acacia gum. Beyond these values both gums decreased the release with different efficiency. From release decreasing point of view tragacanth was much more efficient than acacia gum as it was evident from steeper slopes of its descending efficiency curves. The most suitable kinetic model for tragacanth release was zero order one with rate constant of 0.0007 - 0.0011 fraction/min whereas Weibull and log probability models were applicable for acacia matrices. Because of zero order kinetic as well as stronger release retardation efficiency the tragacanth matrices were superior to acacia matrices.

Tumoral calcinosis is an inherited disorder characterized by periarticular calcified masses and hyperphosphatemia. It is associated with increased serum 1,25 dihydroxy-vitamin D and serum phosphate. Surgical extraction of the tumor masses may lead to new lesions and pharmacologic therapies have produced only limited success. We present an 18 year old man with multiple periarticular soft tissue masses and hyperphosphatemia. After biochemical and pathological assessments, primary tumoral calcinosis was diagnosed and the patient was treated with acetazolamide. After four weeks of therapy with acetazolamide soft tissue, masses regressed significantly, and the serum phosphate level returned to the normal range. Keywords: